Data from in vivo research, however, allows us to highlight that PAI-1 antagonists might be an effective intervention to prevent the development of obesity and its sequelae by restoring leptin responsiveness with improved energy dissipation and thermogenic control. This evidence concerns the gene SERPINE1 and obesity due to melanocortin 4 receptor deficiency.